ArticlePharmaceutics2025

Development and Evaluation of Bilayer Sustained-Release Tablets of Ruxolitinib Using Discriminative Pharmacokinetic Analysis and IVIVC.

Namhyuck Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.